Sydney Adventist Hospital 02 9487 9111

Sydney Adventist Hospital
« View pages

Clinical Specialties

Breast Cancer Clinical Trials


Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence


An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer and tamoxifen vs anastrozole in postmenopausal women with hormone sensitive DCIS


CRAD001Y2201: Three arm randomised, open label phase 2 study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with oestrogen receptor positive , locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole


A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer


A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have received two or more prior HER2- Directed Regimens in the Metastatic Setting (NALA)


A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting


A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

PUMA 6201 - Recruiting

An Open-Label Study to Characterize the Incidence and Severity of Diarrhoea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

CONTESSA - Recruiting

A multinational, multicenter, randomized, open-label, parallel group Phase 3 study to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive MBC previously treated with a taxane in the neoadjuvant or adjuvant setting

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services